MONTREAL, October 5, 2013 /PRNewswire/ --
-- Dr Andreas Nikolis to present at the 22ndCongress of the European Academy of Dermatology and Venereology (EADV)
On the heels of receiving its Medical Device License from Health Canada for the Klox Biophotonic System for the treatment of acne vulgaris, (also known as the Lumigel Cleanse System), KLOX Technologies Inc. ("KLOX") announced today that it will be presenting on October 5th its facial rejuvenation technology at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Turkey. Dr. Andreas Nikolis' presentation is entitled "Biophotonics in facial rejuvenation. A prospective randomized investigative trial".
DATEBOOK:
22ndCongress of the European Academy of Dermatology and Venereology (EADV)- October 5th, 2013, Istanbul (Turkey)
- Biophotonics in facial rejuvenation. A prospective randomized investigative trial.
Presenter: Dr. Andreas Nikolis, Plastic, Reconstructive and Aesthetic Surgeon, Associate Professor of Plastic Surgery, Division of Plastic Surgery, University of Montreal.
Saturday, October 5th, - 8:09 AM / 8:18 AM (EEST), ICC Istanbul Congress Center TaÅŸkiÅŸla, Street Harbiye, (Üsküdar 3 room), Istanbul
KLOX representatives will be at kiosk 123 for the duration of the event.
ON TWITTER
KLOX Technologies corporate account: @KLOXTech
About KLOX Technologies: Leveraging light-based biophotonic technologies
http://www.kloxtechnologies.com/en/investor-relations
KLOX is a privately-owned company focused on the development and commercialization of a unique, non-invasive biophotonic technology using a primary device consisting of a multiple LED lighting system that interacts with an oxygen-rich gel containing light-trapping molecules. KLOX's cosmetics and medical devices are destined for the rapidly growing aesthetics, dermatological, tissue repair and dental markets.
INFORMATION: Roch Landriault
NATIONAL Public Relations
+1 (514) 843-2345
rlandriault@national.ca
